natgillin/translations-raw huggingface dataset:
In the subgroup of patients with HR ≥75 bpm (n = 4,150), a greater reduction was observed in the primary composite endpoint of 24% (hazard ratio: 0.76, 95% CI [0.68;0.85] - p <0.0001) and for other secondary endpoints, including all cause death (hazard ratio: 0.83, 95% CI [0.72;0.96] - p = 0.0109) and CV death (hazard ratio: 0.83, 95% CI [0.71;0.97] - p = 0.0166). 
U podskupini bolesnika sa srčanom frekvencijom ≥ 75/min (n=4 150), zabilježeno je izraženije smanjenje primarne kompozitne mjere ishoda od 24% (omjer hazarda (HR): 0,76, 95%CI [0,68;0,85]p< 0,0001) kao i za ostale sekundarne mjere ishoda, uključujući smrt zbog svih uzroka (omjer hazarda (HR): 0,83, 95%CI [0.72;0.96] - p=0,0109) i smrt zbog kardiovaskularnih uzroka (omjer hazarda (HR): 0,83, 95%CI [0.71;0.97] - p=0,0166).
In some cases (e.g. if you are elderly), your doctor may prescribe half the dose i.e., one half 5 mg tablet of Ivabradine JensonR 5 mg (corresponding to 2.5 mg ivabradine) in the morning and one half 5 mg tablet in the evening. 
U nekim slučajevima (npr. kod starijih osoba) postoji mogućnost da Vam liječnik propiše pola doze, t.j. jednu polovicu tablete od 5mg lijeka Ivabradine JensonR 5 mg (što odgovara količini od 2,5 mg ivabradina) ujutro i jednu polovicu tablete od 5 mg uvečer.
If you stop taking Ivabradine JensonR: 
Ako prestanete uzimati Ivabradine JensonR:
Ivabradine JensonR is available in blister packs of 14, 14 x 1, 28, 56, 56 x 1, 98 and 112 film-coated tablets. 
Ivabradine JensonR dostupan je u blister pakiranjima s 14, 14 x 1, 28, 56, 56 x 1, 98 i 112 filmom obloženih tableta.
Make sure to tell your doctor if you are taking any of the following medicines, as a dose adjustment of Ivabradine JensonR or monitoring should be required: - fluconazole (an antifungal medicine) - rifampicin (an antibiotic) - barbiturates (for difficult sleeping or epilepsy) - phenytoin (for epilepsy) - Hypericum perforatum or St John's wort (herbal treatment for depression) - QT prolonging medicines to treat either heart rhythm disorders or other conditions: - quinidine, disopyramide, ibutilide, sotalol, amiodarone (to treat heart rhythm disorders) - bepridil (to treat angina pectoris) - certain types of medicines to treat anxiety, schizophrenia or other psychoses (such as pimozide, ziprasidone, sertindole) - anti-malarial medicines (such as mefloquine or halofantrine) - intravenous erythromycin (an antibiotic) - pentamidine (an antiparasitic medicine) - cisapride (against the gastro-oesophageal reflux) - Some types of diuretics which may cause decrease in blood potassium level, such as furosemide, hydrochlorothiazide, indapamide (used to treat oedema, high blood pressure). 
Ako uzimate neke od slijedećih lijekova, svakako o tome obavijestite svog liječnika koji bi trebao prilagoditi dozu Ivabradine JensonR ili pratiti liječenje: - flukonazol (antifungik) - rifampicin (antibiotik) - barbiturati (za otežano spavanje ili epilepsiju) - fenitoin (za epilepsiju) - Hypericum perforatum ili gospina trava (biljna terapija za depresiju) - lijekovi koji produljuju QT-interval i primjenjuju se za liječenje poremećaja srčanog ritma ili drugih bolesti: - kinidin, dizopiramid, ibutilid, sotalol, amiodaron (za liječenje poremećaja srčanog ritma) - bepridil (za liječenje angine pektoris) - lijekovi za liječenje anksioznosti, shizofrenije ili drugih psihoza (kao što su pimozid, ziprasidon, sertindol) - antimalarici (kao npr. meflokin ili halofantrin) - intravenski eritromicin (antibiotik) - pentamidin (antiparazitik) - cisaprid (za liječenje gastro-ezofagealnog refluksa) - Neke vrste diuretika koji mogu uzrokovati sniženje razine kalija u krvi, poput furosemida, hidroklorotiazida, indapamida (koriste se za liječenje edema, povišenog krvnog tlaka).
EU/1/16/1145/018 EU/1/16/1145/019 EU/1/16/1145/020 EU/1/16/1145/021 EU/1/16/1145/022 EU/1/16/1145/023 EU/1/16/1145/024 EU/1/16/1145/025 EU/1/16/1145/026 EU/1/16/1145/027 EU/1/16/1145/028 EU/1/16/1145/029 EU/1/16/1145/030 EU/1/16/1145/031 EU/1/16/1145/032 EU/1/16/1145/033 EU/1/16/1145/034 
EU/1/16/1145/018 EU/1/16/1145/019 EU/1/16/1145/020 EU/1/16/1145/021 EU/1/16/1145/022 EU/1/16/1145/023 EU/1/16/1145/024 EU/1/16/1145/025 EU/1/16/1145/026 EU/1/16/1145/027 EU/1/16/1145/028 EU/1/16/1145/029 EU/1/16/1145/030 EU/1/16/1145/031 EU/1/16/1145/032 EU/1/16/1145/033
EU/1/16/1145/001 EU/1/16/1145/002 EU/1/16/1145/003 EU/1/16/1145/004 EU/1/16/1145/005 EU/1/16/1145/006 EU/1/16/1145/007 EU/1/16/1145/008 EU/1/16/1145/009 EU/1/16/1145/010 EU/1/16/1145/011 EU/1/16/1145/012 EU/1/16/1145/013 EU/1/16/1145/014 EU/1/16/1145/015 
EU/1/16/1145/001 EU/1/16/1145/002 EU/1/16/1145/003 EU/1/16/1145/004 EU/1/16/1145/005 EU/1/16/1145/006 EU/1/16/1145/007 EU/1/16/1145/008 EU/1/16/1145/009 EU/1/16/1145/010 EU/1/16/1145/011 EU/1/16/1145/012 EU/1/16/1145/013 EU/1/16/1145/014 EU/1/16/1145/015 EU/1/16/1145/016
Ivabradine JensonR is also available in bottles with a screw cap and a desiccant of 56, 98 and 100 film-coated tablets. 
Ivabradine JensonR dostupan je u bocama s navojnim čepom i sredstvom za sušenje s 56, 98 i 100 filmom obloženih tableta.
Mylan Hungary Kft. Mylan utca. 
Mylan Hungary Kft.
In pivotal phase III clinical trials the following medicinal products were routinely combined with ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-platelet medicinal products. 
U pivotalnim kliničkim ispitivanjima faze III, sljedeći lijekovi su rutinski primjenjivani s ivabradinom bez štetnih utjecaja: inhibitori konvertaze angiotenzina, antagonisti angiotenzina II, beta- blokatori, diuretici, antagonisti aldosterona, nitrati brzog i dugog djelovanja, inhibitori HMG CoA reduktaze, fibrati, blokatori protonske pumpe, oralni antidijabetici, acetilsalicilatna kiselina. i drugi antitrombocitni lijekovi.
Mon → Tue → Wed → Thu → Fri → Sat → Sun 
DRUGO pon → uto → sri → čet → pet → sub → ned
N-desmethylated derivative of ivabradine has been identified as the main active metabolite in humans. 
Kao glavni aktivni metabolit u ljudi identificiran je N-desmetilirani derivat ivabradina.
Ivabradine did not show additional efficacy on secondary endpoints of ETT parameters at the trough of drug activity while an additional efficacy was shown at peak (3-4 hours after oral ivabradine intake). 
Ivabradin nije pokazao dodatnu djelotvornost u sekundarnim mjerama ishoda - parametrima testa opterećenja, pri najnižoj koncentraciji lijeka dok je pri vršnoj koncentraciji lijeka uočena dodatna djelotvornost (3-4 sata nakon peroralnog uzimanja ivabradina).
If you forget to take Ivabradine JensonR: 
Ako ste zaboravili uzeti Ivabradine JensonR:
Do not take Ivabradine JensonR if you are able to become pregnant unless you use reliable contraceptive measures (see “Do not take Ivabradine JensonR”). 
Nemojte uzimati Ivabradine JensonR ako ste žena koja može zatrudnijeti, osim u slučaju da koristite pouzdanu kontracepciju (pogledajte dio „Nemojte uzimati Ivabradine JensonR”).
The pack sizes 14 x 1 and 56 x 1 film-coated tablets are presented in unit dose blisters. 
Pakiranja s 14 x 1 i 56 x 1 filmom obloženom tabletom u obliku su blistera djeljivih na jedinične doze.
PVC/Aclar-Alu perforated unit dose pack in pack sizes of 14 x 1 and 56 x 1 film-coated tablets. 
PVC/Aclar-Al perforirani blisteri djeljivi na jedinične doze u pakiranjima od 14 x 1 i 56 x 1 filmom obloženom tabletom.
- The other ingredients in the tablet core are: lactose anhydrous, magnesium stearate, maltodextrin, microcrystalline cellulose, colloidal anhydrous silica, hydroxypropyl cellulose, and in the tablet coating are : hypromellose, titanium dioxide, macrogol, polysorbate 80, yellow iron oxide (E172), red iron oxide (E172). 
- Pomoćne tvari u jezgri tablete su: bezvodna laktoza, magnezijev stearat, maltodekstrin, mikrokristalična celuloza, koloidni bezvodni silicijev dioksid, hidroksipropilceluloza, a u ovojnici tablete: hipromeloza, titanijev dioksid, makrogol, polisorbat 80, žuti željezov oksid (E172), crveni željezov oksid (E172).
Other medicines and Ivabradine JensonR Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Cold form blisters (OPA/Alu/PVC) in pack sizes of 14, 28, 56, 98 and 112 film-coated tablets. 
Hladno oblikovani blisteri (OPA/Al/PVC) u pakiranjima od 14, 28, 56, 98 i 112 filmom obloženih tableta.
In the subgroup of patients with HR ≥75 bpm and on the recommended target dose of beta-blocker, no statistically significant benefit was observed on the primary composite endpoint (hazard ratio: 0.97, 95%CI [0.74; 1.28]) and other secondary endpoints, including hospitalisation for worsening heart failure (hazard ratio: 0.79, 95% CI [0.56;1.10]) or death from heart failure (hazard ratio: 0.69, 95% CI [0.31;1.53]). 
U podskupini bolesnika sa srčanom frekvencijom ≥ 75/min koji primaju preporučenu ciljnu dozu beta-blokatora nije zabilježena značajna korist za primarni kompozitni ishod (omjer hazarda (HR): 0,97, 95%CI [0,74;1,28]) niti za ostale sekundarne ishode uključujući hospitalizaciju zbog pogoršanja zatajenja srca (omjer hazarda (HR): 0,79, 95% CI [0,56;1,10]) ili smrt zbog zatajenja srca (omjer hazarda (HR): 0,69, 95% CI [0,31;1,53]).
In a 1,277-patients randomised placebo-controlled study, ivabradine demonstrated a statistically significant additional efficacy on response to treatment (defined as a decrease of at least 3 angina attacks per week and/or an increase in the time to 1 mm ST segment depression of at least 60 s during a treadmill ETT) on top of amlodipine 5 mg o.d. or nifedipine GITS 30 mg o.d. at the trough of drug activity (12 hours after oral ivabradine intake) over a 6-week treatment period (OR = 1.3, 95% CI [1.0-1.7]; p = 0.012). 
U randomiziranom, placebom kontroliranom ispitivanju na 1277 bolesnika, primjena ivabradina uz postojeću primjenu amlodipina od 5 mg jednom dnevno ili nifedipina GITS (gastrointestinalni terapijski sustav) od 30 mg jednom dnevno pri najnižoj koncentraciji lijeka (12 sati nakon uzimanja ivabradina peroralno) pokazala je statistički značajnu dodatnu djelotvornost u odgovoru na liječenje (definiran kao smanjenje od najmanje 3 napadaja angine na tjedan i/ili povećanje vremena do depresije ST segmenta za 1 mm od najmanje 60 s za vrijeme testa opterećenja) tijekom 6 tjedana liječenja (omjer šansi (OR) = 1,3, 95% CI [1,0-1,7]; p=0,012).
A 20% heart rate reduction, without bradycardia, was achieved by 69.9% of patients in the ivabradine group versus 12.2% in the placebo group during the titration period of 2 to 8 weeks (Odds Ratio: E = 17.24, 95% CI [5.91; 50.30]). 
U 69,9% bolesnika koji su primali ivabradin postignuto je 20% sniženje broja otkucaja srca bez bradikardije u usporedbi s 12,2% bolesnika u skupini koja je primala placebo tijekom titracije doza u razdoblju od 2 do 8 tjedana (omjer izgleda E = 17,24, 95% CI [5,91; 50,30]).
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Resting heart rate below 70 beats per minute prior to treatment - Cardiogenic shock - Acute myocardial infarction - Severe hypotension (<90/50 mmHg) - Severe hepatic insufficiency - Sick sinus syndrome - Sino-atrial block - Unstable or acute heart failure - Pacemaker dependent (heart rate imposed exclusively by the pacemaker) - Unstable angina - AV-block of 3rd degree - Combination with strong cytochrome P450 3A4 inhibitors such as azole antifungals (ketoconazole, 
- Preosjetljivost na djelatnu tvar ili na neku od pomoćnih tvari navedenih u dijelu 6.1 - Srčana frekvencija u mirovanju prije liječenja sporija od 70 otkucaja u minuti - Kardiogeni šok - Akutni infarkt miokarda - Teška hipotenzija (< 90/50 mmHg) - Teška insuficijencija jetre - Sindrom bolesnog sinusnog čvora - Sinusatrijski blok - Nestabilno ili akutno zatajenje srca - Bolesnici s ugrađenim elektrostimulatorom (broj otkucaja srca isključivo ovisi o pacemakeru)
PVC/Aclar-Alu blisters in pack sizes of 14, 28, 56, 98 and 112 film-coated tablets. 
PVC/Aclar-Al blisteri u pakiranjima od 14, 28, 56, 98 i 112 filmom obloženih tableta.
Do not take Ivabradine JensonR if you are breast-feeding (see “Do not take Ivabradine JensonR”). 
Ne uzimajte Ivabradine JensonR ako dojite (vidjeti “Nemojte uzimati Ivabradine JensonR”).
Uncommon* 
Manje često*
HIV protease inhibitors (nelfinavir, ritonavir) and nefazodone (see sections 4.5 and 5.2) - Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties (see section 4.5) - Pregnancy, lactation and women of child-bearing potential not using appropriate contraceptive measures (see section 4.6) 
- Istodobna primjena s verapamilom ili diltiazemom koji su umjereni inhibitori CYP3A4 s učinkom na smanjenje srčane frekvencije (vidjeti dio 4.5) - Trudnoća, dojenje i žene reproduktivne dobi koje ne koriste prikladne mjere kontracepcije (vidjeti dio 4.6)
If heart rate increases persistently above 60 beats per minute at rest, the dose can be up titrated to the next upper dose in patients receiving 2.5 mg twice daily or 5 mg twice daily. 
Ukoliko je srčana frekvencija stalno iznad 60 otkucaja u minuti u mirovanju doza se može titrirati na višu dozu u bolesnika koji uzimaju 2,5 mg dva puta dnevno ili 5 mg dva puta dnevno.
The dose was adapted depending on the therapeutic response with maximum doses of 0.2 mg/kg bid, 0.3 mg/kg bid and 15 mg bid respectively. 
Doza se prilagodila ovisno o terapijskom odgovoru s maksmimalnim dozama do 0,2 mg/kg/dan dva puta na dan, 0,3 mg/kg/dan dva puta na dan i 15 mg/kg/dan dva puta na dan, ovisno o starosnoj podskupini.
If, during treatment, heart rate decreases below 50 beats per minute (bpm) at rest or the patient experiences symptoms related to bradycardia such as dizziness, fatigue or hypotension, the dose must be titrated downward including the lowest dose of 2.5 mg twice daily (one half 5 mg tablet twice daily). 
Ukoliko tijekom liječenja srčana frekvencija padne ispod 50 otkucaja u minuti (50/min) u mirovanju ili u bolesnika nastupe simptomi koji su povezani s bradikardijom, kao što su omaglica, umor ili hipotenzija, doza se mora titrirati na nižu, uključujući najnižu dozu od 2,5 mg dva puta na dan (polovica tablete od 5 mg dva puta dnevno).
This increase in heart rate can cause the chest pain in people who suffer from angina. 
U ljudi koji boluju od angine, to povećanje brzine srčanih otkucaja može uzrokovati bol u prsnom košu.
If, during treatment, resting heart rate decreases persistently below 50 bpm or the patient experiences symptoms related to bradycardia such as dizziness, fatigue or hypotension, the dose must be titrated downward or treatment discontinued if heart rate below 50 bpm or symptoms of bradycardia persist (see section 4.2). 
Ukoliko se, tijekom liječenja, srčana frekvencija u mirovanju neprestano uspori na manje od 50/min, ili ako bolesnik osjeti simptome koji su povezani s bradikardijom, kao što su omaglica, umor ili hipotenzija, doza se mora titrirati na sljedeću nižu dozu ili se liječenje mora prekinuti ukoliko frekvencija u mirovanju ostane manje od 50/min ili perzistiraju simptomi bradikardije (vidjeti dio 4.2).
- in clinical electrophysiology studies, ivabradine had no effect on atrioventricular or intraventricular conduction times or corrected QT intervals; - in patients with left ventricular dysfunction (left ventricular ejection fraction (LVEF) between 30 and 45%), ivabradine did not have any deleterious influence on LVEF. 
- u bolesnika s disfunkcijom lijeve klijetke (istisna frakcija lijeve klijetke (LVEF) između 30 i 45%), ivabradin nije imao nikakav štetan učinak na LVEF.
If during treatment, heart rate decreases persistently below 50 beats per minute (bpm) at rest or the patient experiences symptoms related to bradycardia, the dose must be titrated downward to the next lower dose in patients receiving 7.5 mg twice daily or 5 mg twice daily. 
Ukoliko se, tijekom liječenja, nastavi usporavati srčana frekvencija ispod 50 otkucaja u minuti (50/min) u mirovanju, ili u bolesnika nastupe simptomi koji su povezani s bradikardijom, doza se mora titrirati na sljedeću nižu u bolesnika koji primaju 7,5 mg dva puta dnevno ili 5 mg dva puta dnevno.
What Ivabradine JensonR looks like and contents of the pack Ivabradine JensonR 5 mg tablets are pink-coloured, oval shaped film-coated tablets scored on both sides, marked with “ I 5” on one side and “M” on the other side of the tablet. 
Kako Ivabradine JensonR izgleda i sadržaj pakiranja Ivabradine JensonR 5 mg tablete ružičaste su, ovalne, filmom obložene tablete s urezom na obje strane, s oznakom „I 5” na jednoj strani i „M” na drugoj strani.
What Ivabradine JensonR looks like and contents of the pack Ivabradine JensonR 7.5 mg tablets are pink-coloured, round film-coated tablets marked with “I 7” on one side and “M” on the other side of the tablet. 
Kako Ivabradine JensonR izgleda i sadržaj pakiranja Ivabradine JensonR 7,5 mg tablete ružičaste su, okrugle, filmom obložene tablete, s oznakom „I 7” na jednoj strani i „M” na drugoj strani.
Pharmacokinetic/pharmacodynamic (PK/PD) relationship PK/PD relationship analysis has shown that heart rate decreases almost linearly with increasing ivabradine and S 18982 plasma concentrations for doses of up to 15-20 mg twice daily. 
Farmakokinetički/farmakodinamički (PK/PD) odnos Analiza PK/PD odnosa pokazala je da se srčana frekvencija gotovo linearno smanjuje, kako se povećavaju koncentracije ivabradina i metabolita
Ivabradine JensonR 5 mg film-coated tablets Each film-coated tablet contains 5 mg ivabradine (as hydrochloride). 
Ivabradine JensonR 5 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 5 mg ivabradina (u obliku ivabradinklorida).
How to take Ivabradine JensonR 
Kako uzimati Ivabradine JensonR
Ivabradine JensonR 7.5 mg film-coated tablets Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride). 
Ivabradine JensonR 7,5 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 7,5 mg ivabradina (u obliku ivabradinklorida).
Each film-coated tablet contains 5 mg ivabradine (as hydrochloride). 
Jedna filmom obložena tableta sadrži 5 mg ivabradina (u obliku ivabradinklorida).
How does Ivabradine JensonR work 
Kako djeluje Ivabradine JensonR
Common (may affect more than 1 in 10 people): 
Često (mogu se javiti u više od 1 na 10 osoba):
Ivabradine JensonR 5 mg film-coated tablets ivabradine 
Ivabradine JensonR 5 mg filmom obložene tablete ivabradin
AV 1st degree block (ECG prolonged PQ interval) Ventricular extrasystoles Atrial fibrillation Palpitations, supraventricular extrasystoles 
Ventrikularne ekstrasistole Fibrilacija atrija
Ivabradine does not influence intracardiac conduction, contractility (no negative inotropic effect) or ventricular repolarisation: 
Ivabradin ne utječe na intrakardijalno provođenje, kontraktilnost (nema negativnog inotropnog učinka) ili na ventrikulsku repolarizaciju: - u kliničkim ispitivanjima elektrofiziologije, ivabradin nije imao učinka na atrioventrikulska ili na intraventrikulska vremena provođenja ili korigirane QT-intervale;
Ivabradine JensonR 7.5 mg film-coated tablets ivabradine 
Ivabradine JensonR 7,5 mg filmom obložene tablete ivabradin
As the treatment for angina or chronic heart failure is usually life-long, you should discuss with your doctor before stopping this medicinal product. 
Liječenje angine ili kroničnog zatajenja srca obično je doživotno.
NAME OF THE MEDICINAL PRODUCT Ivabradine JensonR 5 mg film-coated tablets Ivabradine JensonR 7.5 mg film-coated tablets 
Ivabradine JensonR 5 mg filmom obložene tablete Ivabradine JensonR 7,5 mg filmom obložene tablete
INFORMATION IN BRAILLE Ivabradine JensonR 5 mg film-coated tablets 
16. PODACI NA BRAILLEOVOM PISMU Ivabradine JensonR 5 mg filmom obložene tablete
INFORMATION IN BRAILLE Ivabradine JensonR 7.5 mg film-coated tablets 
16. PODACI NA BRAILLEOVOM PISMU Ivabradine JensonR 7,5 mg filmom obložene tablete
Uncontrolled blood pressure Hypotension, possibly related to bradycardia 
Hipotenzija, moguće povezana s bradikardijom
Pink colour, oval shape, biconvex film-coated scored tablets, approximately 7.9 mm by 4.15 mm debossed with “Ι 5” on one side and “M” on other side of the tablet. 
Ivabradine JensonR 5 mg filmom obložene tablete Ružičaste, ovalne, bikonveksne, filmom obložene tablete s urezom, približne veličine 7,9 mm × 4,15 mm s utisnutom oznakom „Ι 5” na jednoj strani i „M” na drugoj strani.
Pink colour, round, beveled edge, biconvex film-coated tablets, approximately 6.65 mm in diameter debossed with “Ι 7” on one side and “M” on other side of the tablet. 
Ivabradine JensonR 7,5 mg filmom obložene tablete Ružičaste, okrugle, filmom obložene bikonveksne tablete s ukošenim rubom, približnog promjera 6,65 mm s utisnutom oznakom „I 7” na jednoj strani i „M” na drugoj strani.
Other concomitant use 
Istodobna primjena drugih lijekova
The intake of St John's wort should be restricted during the treatment with ivabradine. 
Tijekom liječenja s ivabradinom potrebno je ograničiti uzimanje gospine trave.
Asthenia, possibly related to bradycardia 
Omaglica, moguće povezano s bradikardijom
The 
Vid
Headache, generally during the first month of treatment Dizziness, possibly related to bradycardia 
Astenija, moguće povezana s bradikardijom Umor, moguće povezan s bradikardijom Malaksalost, moguće povezano s bradikardijom
STATEMENT OF ACTIVE SUBSTANCE) Each film-coated tablet contains 5 mg ivabradine (as hydrochloride) 
NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži 5mg ivabradina (u obliku ivabradinklorida).
STATEMENT OF ACTIVE SUBSTANCE Each film-coated tablet contains 7.5 mg ivabradine (as hydrochloride) 
NAVOĐENJE DJELATNE(IH) TVARI Jedna filmom obložena tableta sadrži 7,5mg ivabradina (u obliku ivabradinklorida).
Talk to your doctor or pharmacist before taking Ivabradine JensonR - if you suffer from heart rhythm disorders (such as irregular heartbeat, palpitation, increase in chest pain) or sustained atrial fibrillation (a type of irregular heartbeat), or an abnormality of electrocardiogram (ECG) called ‘long QT syndrome', - if you have symptoms such as tiredness, dizziness or shortness of breath (this could mean that your heart is slowing down too much), - if you suffer from symptoms of atrial fibrillation (pulse rate at rest unusually high (over 110 beats per minute) or irregular, without any apparent reason, making it difficult to measure), - if you have had a recent stroke (cerebral attack), - if you suffer from mild to moderate low blood pressure, - if you suffer from uncontrolled blood pressure, especially after a change in your antihypertensive treatment, - if you suffer from severe heart failure or heart failure with abnormality of ECG called ‘bundle branch block', - if you suffer from chronic eye retinal disease, - if you suffer from moderate liver problems, - if you suffer from severe renal problems 
(iznad 110 otkucaja u minuti) ili nepravilna, bez jasnog razloga, što otežava njezino mjerenje), - ako ste nedavno imali moždani udar, - ako imate blago ili umjereno niski krvni tlak, - ako bolujete od visokog krvnog tlaka koji nije dobro kontroliran, osobito nakon promjene u terapiji - ako bolujete od teškog kroničnog srčanog zatajenja ili srčanog zatajenja s abnormalnošću EKG
Suspension (inactivated) 
Suspenzija(inaktivirana)
≥ 2.0 IU*** 
≥ 2,0 IJ***
--1 Lyophilisate (live attenuated) Canine distemper virus, strain CDV Bio 11/A 
--1 Liofilizat (živi atenuirani) Virus štenećaka, soj CDV Bio 11/A
Leptospira interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 
Leptospira interrogans serogrupa Icterohaemorrhagiae serovar Icterohaemorrhagiae, soj MSLB 1089
Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 
Leptospira interrogans serogrupa Australis serovar Bratislava, soj MSLB 1088
Leptospira interrogans serogroup Canicola serovar Canicola, strain MSLB 
Leptospira interrogans serogrupa Canicola serovar Canicola, soj MSLB 1090